LBAs and critical reagents

When making pivotal decisions in support of drug development, data from ligand-binding assays (LBAs) can be difficult to manage. The robustness and reliability of the assay is directly influenced by the long-term availability and quality of the critical reagents used. Critical reagents are the key components used in LBAs and include antibodies, biologics, peptides, as well as solid supports and matrices.

This Spotlight will explore key aspects of LBA design, the importance of critical reagent management, different strategies of life-cycle management, challenges that arise when changing reagents and current perspectives on critical reagent expiry and re-test dates.

This feature was produced in association with Frontage Laboratories, Inc.